Substance / Medication

Altretamine

Overview

Active Ingredient
altretamine
RxNorm CUI
5296

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner Michael J, McMorris Trevor C, Rojas Rafael J et al. · Cancer Chemother Pharmacol · 2008
PMID: 18305940Observational
Oral altretamine used as salvage therapy in recurrent ovarian cancer.
Chan John K, Loizzi Vera, Manetta Alberto et al. · Gynecol Oncol · 2004
PMID: 14751188Case Report
Mode of interaction of altretamine with calf thymus DNA: biophysical insights.
Goswami Sathi, Ghosh Ritutama, Prasanthan Pooja et al. · J Biomol Struct Dyn · 2023
PMID: 35343872Other
The Combined Anti-Tumor Efficacy of Bioactive Hydroxyapatite Nanoparticles Loaded with Altretamine.
Alghazwani Yahia, Venkatesan Krishnaraju, Prabahar Kousalya et al. · Pharmaceutics · 2023
PMID: 36678930OtherFull text (PMC)
The effect of cation-π interactions on the stability and electronic properties of anticancer drug Altretamine: a theoretical study.
Alirezapour Fahimeh, Khanmohammadi Azadeh · Acta Crystallogr C Struct Chem · 2020
PMID: 33016269Other
Anticancer altretamine recognition by bovine serum albumin and its role as inhibitor of fibril formation: Biophysical insights.
Ghosh Ritutama, Bharathkar Sonya K, Kishore Nand · Int J Biol Macromol · 2019
PMID: 31323265Preclinical
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
Keldsen Nina, Havsteen Hanne, Vergote Ignace et al. · Gynecol Oncol · 2003
PMID: 12586589Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Altretamine (substance)
SNOMED CT
387385000
UMLS CUI
C0019453
RxNorm CUI
5296

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.